In the cross-sectional analysis we found a prevalence rate for CIN3+ of 0.4% among all women, including HC2-/ APTIMA-/LBC-positives and triple negatives (prevalence). We assumed that the incidence within the group of triple negatives was at most equal to the prevalence of 0.4% found in the cross-sectional study including test positives. This was a very conservative assumption as the cumulative incidence after 5 years was to be expected smaller than the prevalence and triple negatives should have a smaller incidence as the entire group. The assumption of 0.4% incident cases within triple negatives corresponds to an NPV (negative predictive value) of 99.6%. This NPV is used as the alternative in a statistical test. With n= 4000 a value of 99.3% could be rejected in a one-sided statistical test with a level of significance of 5% and a statistical power of 80%.
Estimating the cumulative risk of CIN3+ (and CIN2+): further details
Note that if a woman failed to attend colposcopy after that visit, but disease was found on the next visit, it was counted as if she had attended straight away and disease was found at that time. Similarly, if a woman failed to attend colposcopy but subsequently either had a negative colposcopy or an all-negative screen, it was counted as if she had attended colposcopy (and did not have disease) at the earlier visit. Everyone had a baseline visit. The rule we have used here moving some outcomes from visit 1 to baseline, means that the 
